uniQure announces FDA's Breakthrough Therapy designation for AMT-130, with promising Phase I/II trial safety data and upcoming regulatory updates. uniQure N.V. has announced that its gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback